Phase II study of SU5416 - A small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - In patients with refractory myeloproliferative diseases
Francis J. Giles, Maureen A. Cooper, Lewis Silverman, Judith E. Karp, Jeffrey E. Lancet, Maurizio Zangari, Paul J. Shami, Khuda D. Khan, Alison L. Hannah, Julie M. Cherrington, Deborah A. Thomas, Guillermo Garcia-Manero, Maher Albitar, Hagop M. Kantarjian, Alison T. Stopeck
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Phase II study of SU5416 - A small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - In patients with refractory myeloproliferative diseases'. Together they form a unique fingerprint.